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There is now adequate evidence to indicate that liver fi-
brosis is a dynamic rather than a static process and as effec-
tive antiviral and other specific therapies became available, 
fibrosis and even cirrhosis could become reversible (1, 2). 
Effective and early therapy of viral and autoimmune hepa-
titis could result in reversibility of cirrhosis in addition to 
clinical cure (1-3). Therefore, we urgently need to be able to 
follow the progression or regression of fibrosis in response 
to therapy in addition to initial assessment of fibrosis by 
liver biopsy. Liver biopsy which was first introduced in 1923 
has been used widely in the diagnosis of liver diseases and is 
still the gold standard reference for the assessment of liver 
fibrosis during the course of chronic liver diseases (4, 5). 
But this procedure is costly, painful and runs a small risk of 
sever complications like hemorrhage and even death; there-
fore, it is unacceptable to patients and doctors alike (5). It is 
also time-consuming and labor-intensive; the assessment is 
subjective and due to small size of the specimen in setting 
of heterogeneity of liver fibrosis is prone to sampling error. 
There is now increasing evidence that sampling error (up 
to 35%), inter- and intra-observer variability (up to 20%) for 
a particular stage between pathologist are major problems 
which may preclude accurate fibrosis staging for individual 
patients with liver biopsy (4-6). For the said reasons and 
especially  in  chronic  liver  disease  where  monitoring  the 
evolution of disease or response to treatment may require 
repeated  assessments,  the  discipline  of  hepatology  need 
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to find a reliable and noninvasive alternative method to re-
place this old procedure. Finding a noninvasive method for 
assessment of liver fibrosis has become a real challenge for 
hepatologists during the last two decades. This is especially 
true given that chronic liver diseases affect hundreds of mil-
lions of people worldwide, the majority of which living in 
Asian countries (7-9).
Several methods have been proposed to noninvasively stage 
liver fibrosis including a variety of imaging modalities and 
a range of biochemical tests (10-12). The blood tests or their 
composite scores like Fibro Test or aspartate aminotrans-
ferase to platelets ratio index (APRI) (11) or serum fibrosis 
marker such as hyaluronic acid (12) have been shown to be 
of limited diagnostic value especially in HBV-related chronic 
liver disease. The imaging modalities include ultrasound-
based transient elastography (TE) (10), magnetic resonance 
elastography (13) and fibrocomputed tomography (14). Ac-
cording to available evidence fibrocomputed tomography 
and  magnetic  resonance  elastography  which  require  the 
involvement of a radiologist with extensive training and a 
lot of financial investment, do not seem to have clear advan-
tages in staging fibrosis when compared to TE.
In this issue of Hepatitis Monthly, Sporea and colleagues 
(15) used fibroscan to measure liver stiffness and estimate 
the extent of fibrosis in subjects with active and inactive 
chronic HBV infection. They have shown that patients with 
active HBV infection and those with an elevated HBV-DNA 
load have significantly higher fibroscan score compared to 
those with inactive HBV. Although their study have several 
shortcomings including significantly older age of the control 
group patients, absence of viral markers and liver function 
test measurements and sonography in the control group, Hepat Mon. 2011;11(3):157-158
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absence of liver biopsy information especially on those with 
a higher fibroscan score and absence of estimation for vis-
ceral adiposity by waist-to-hip ratio or waist circumference 
measurement, their finding was similar to a previous study 
particularly  in  Asian  population  which  indicates  that  TE 
could be used at least as a screening test to select the chronic 
HBV-infected individual with normal or minimally elevated 
transaminase for liver biopsy (10, 16). Using liver biopsy in 
132 chronic HBV-infected subjects in Tehran (17) with persis-
tently normal ALT, we have shown that up to 30% of them 
(mean age of 32 years) had a Knodell histologic stage of ≥2. 
Further studies comparing the actual histology stage with fi-
broscan measurment is necessary to find out the cutoff value 
in different pouplations. All evidece up to now is supporting 
that TE using fibroscan is a reliable, noninvasive method for 
identification of patients with significant hepatic fibrosis. 
TE is readily reproducible and its score has low inter- and in-
tra-observer variability (10, 16, 18). Several factors were found 
to affect the accuracy of TE for the diagnosis of significant 
fibrosis. These included sever liver congestion, hyperbiliru-
binemia, transaminitis, and prolonged prothrombin time. 
These factors were found to cause a significant overestima-
tion of TE values, leading to false-positive identification of 
fibrosis (10, 18). In addition, TE is impossible in patients with 
ascites and is difficult in obese subjects and those with very 
narrow intercostal spaces. But, its use especially in chronic 
HBV-infected subjects with normal or minimally elevated 
ALT—which constitutes the majority of chronic liver disease 
in Asian population—to select the subject who may benefit 
from oral nucleoside analogue therapy is very attractive.
The accuracy of fibroscan score is excellent for the diagno-
sis of cirrhosis; it is probably the most accurate noninvasive 
method for the early detection of cirrhosis. It is a user-friend-
ly technique that can be performed without any preparation 
in the less than five minutes in clinic or at the bedside, with 
immediate results and high patient acceptance, it is very 
likely that in future it will become the most widely used 
technique for assessment of liver fibrosis (10, 18). Further 
technological improvements are necessary for better appli-
cation of this technique in obese patients and other specific 
populations along with efforts to improve and standardize 
the procedure and adequate operator training (19).
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